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Zhe-yuan Hu1†, Sheng-xian Yuan2†, Yuan Yang2, Wei-ping Zhou2* and Hua Jiang1*Abstract
Background: Karyopherin alpha 2 (KPNA2) promotes tumor growth in hepatocellular carcinoma (HCC). We aimed
to determine the content and clinical significance of mechanism underlying.
Methods: The association of transcriptional factor pleomorphic adenoma gene 1 (PLAG1) with KPNA2 was explored
by co-immunoprecipitation. In vitro gain- and loss-of-function models were established to explore the functional
interaction. Clinical samples from 314 HCC patients were applied to explore the clinical significance.
Results: We found that PLAG1 could associate with KPNA2 and be promoted into nucleus by KPNA2. The increment
of proliferative and metastatic abilities by KPNA2 over-expression can be significantly retarded by PLAG1 inhibition. The
co-enrichment of KPNA2 and PLAG1 in nucleus is observed in clinical samples and can distinguish patients with the
worst prognosis. The positive PLAG1 expression is an independent risk factor of recurrence free survival (HR: 1.766,
1.315-2.371; P = 0.000) and overall survival (HR: 1.589, 1.138-2.220; P = 0.007). Especially for patients with positive KPNA2
staining (N = 152), the positive PLAG1 expression is the sole risk factor for both recurrence free survival (HR: 1.749,
1.146-2.670; P = 0.010) and overall survival (HR: 1.662, 1.007-2.744; P = 0.047).
Conclusions: The nuclear import of PLAG1 by KPNA2 is essential for the role of KPNA2 in HCC cells and is significant
to predict poor survival of HCC patients after hepatectomy.
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Hepatocellular carcinoma (HCC) is the third leading cause
of cancer deaths worldwide, with the incidence on the rise
[1]. The survival of HCC patients after resection remains
poor, mainly attributing to frequent metastases and recur-
rence [2]. Recently, plenty of researches have performed
to explore mechanisms underlying the initiation, propaga-
tion and development of HCC [3,4]. However, the com-
plexity of HCC need further hypothesis-drove researches
to be exerted. Dysfunction of the cellular transport ma-
chinery is commonly observed in multiple cancers includ-
ing HCC [5]. Although some molecules are able to diffuse
through the large Nucleus Pore Complexes (NPCs) in the* Correspondence: ehphwp3@126.com; 41412070@qq.com
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unless otherwise stated.nucleus membrane, factors larger than 45 kDa includ-
ing that associated with malignant diseases need to be
mediated by karyopherin to import into the nucleus [6].
Karyopherin alpha 2 (KPNA2) is one of karyopherin a
family, and could form heterodimer with Karyopherin 1 to
promote nucleus protein import as an adapter protein [7].
Recent studies have illustrated that KPNA2 might be a
critical oncogene and a potential prognostic biomarker in
malignant diseases including HCC [8-11]. Furthermore,
KPNA2 knock-down could significantly inhibit HCC pro-
liferation [12]. But till now, the mechanistic evidence of
KPNA2 in HCC was obscure and deserved to be explored.
Transcriptional factors are widely involved in cancers
and are bound to be enriched in nucleus. It raised the
hypothesis that KPNA2 might affect cancer cells through
the translocation of cancer-associated transcriptional
factors. Previous report has indicated the direct associ-
ation of KPNA2 with a zinc-finger transcription factorsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hybrid system [13], suggesting PLAG1 might be one of
critical mediators of KPNA2 effects in malignant diseases.
PLAG1 was identified as a candidate oncogene in various
malignant cancers. Recent report illustrated the over-
expression of PLAG1 in hepatoblastoma, suggesting a
potential role of PLAG1 in liver malignant disease [14].
Besides, insulin-like growth factor 2 (IGF-II), cellular
retinoic acid binding protein (CRABP2) and cytokine
receptor-like factor 1 (CRLF1), which are confirmed tar-
gets of PLAG1, might be involved in pathological process
of HCC [15,16]. However, whether KPNA2 might associ-
ate with PLAG1 and assist PLAG1 nucleus import to acti-
vate downstream effectors in HCC remains unclassified.
Here, we explored the functional interaction of KPNA2
with PLAG1 and the clinical significance of the mechan-
ism in HCC.
Methods
Clinical specimens and follow-up
The study protocol was approved by the clinical research
ethics committee of Second Military Medical University
(Shanghai, China). Written informed consent was ob-
tained from all patients according to the policies of the
committee. Information that could identify the patients
was not included in this article.
The tissue microarray (TMA) were constructed as de-
scribed previously [17]. Tumoral and corresponding non-
tumoral tissues are separately deposed in different slices.
A HCC cohort with 314 patients was used for immuno-
histochemical staining in TMA. All those HCC patients
received curative hepatectomy at Eastern Hepatobiliary
Surgery Hospital between July 5, 2003 and June 30, 2006.
All HCC specimens were obtained immediately after hep-
atectomy and tissues were then fixed in 10% buffered for-
malin and embedded in paraffin.
The preoperative diagnosis and surgical procedure of
HCC patients was carried out as described previously [18].
The clinical characteristics of HCC cohort are listed in
Table. The differentiation of HCC was defined accord-
ing to the criteria proposed by Edmondson and Steiner.
Micro-metastases were defined as tumors adjacent to
the border of the main tumor and were only observed
under the microscope.
All prognostic information of HCC patients were
checked by phone every 2-3 months during the first 2
years and every 3-6 months thereafter until follow-up
ended on October 28, 2010. Two physicians who were
unaware of the study performed follow-up examinations.
Serum AFP levels and abdominal ultrasound examina-
tions were performed for every month during the first
year after surgery and every 3-6 months thereafter. A
computed tomography and/or magnetic resonance im-
aging examination was performed every 3-6 months orwhen a recurrence were suspected. A diagnosis of recur-
rence was based on preoperative diagnosis criteria. Once
recurrence was confirmed, further treatment was imple-
mented depending on the tumor’s diameter, number, lo-
cation, and vessel invasion as well as the liver function
and performance status.
Cell lines
The Huh7 and SMMC-7721 cells were cultured at 37°C in
an atmosphere containing 5% CO2 in Dulbecco’s Modified
Eagle’s Medium (DMEM) or Modified Eagle’s Medium
(MEM) supplemented with 10% fetal bovine serum.
Extraction of RNA, preparation of cDNA and quantitative
real-time PCR (qRT-PCR)
Total RNA were extracted using Trizol reagent (Takara,
Dalian, China) according to the manufacturer’s instruc-
tions. The quality of the total RNA was assessed by a
Nanodrop 2000 and agarose gel electrophoresis. First-
strand cDNA was synthesized from 1-2 μg of total RNA
using random primers and the M-MLV Reverse Tran-
scriptase (Invitrogen, CA).
Real-time PCR was performed using a StepOne Plus
system (Applied Biosystems, Foster City, CA) with ACTB
as endogenous control. The relative mRNA levels were
calculated based on the Ct values and normalized using
the ACTB expression. The sequences of primers are listed
as: ACTB, Forward: AGTTGCGTTACACCCTTTCTTG,
Reverse: GCTGTCACCTTCACCGTTCC; KPNA2, For-
ward: TGATGGTCCAAATGAACGAAT, Reverse: CTGG
GAAAGACGGCGAGTG; CRLF1, Forward: TGGCTCTC
TTTACGCCCTATTGA, Reverse: TGGCTTGAAAGAG
GAAATCCTT; CRABP2, Forward: TGGGGGTGAATGT
GATGCTG, Reverse: ACGGTGGTGGAGGTTTTGAT;
IGF-II, Forward: AACTGGCCATCCGAAAATAGC, Re-
verse: TTTGCATGGATTTTGGTTTTCAT.
Protein preparation and Western Blot analysis
Total proteins were extracted using RIPA Lysis Buffer
and PMSF (Beyotime Co., China) according to the man-
ufacturer’s instructions. Nucleus proteins were prepared
using Cytoplasmic and Nucleus Protein Extraction Kit
(Fermentas). Antibody dilutions were 1:2000 for KPNA2
(BD, USA), 1:200 for PLAG1 (Biossy, USA), 1:1000 for
Lamin B (Santa Cruz) and 1:5000 for ACTB (Sigma-
Aldrich, USA), respectively. Antibody binding was detected
using an Odyssey infrared scanner (Li-Cor Biosciences Inc).
Construction of in vitro gain or loss-of-function models
Expression vector encoding the human KPNA2 genes
were purchased from Fulen Gen Company (Guangzhou,
China). SiRNAs targeting to KPNA2 and PLAG1 were
synthesized by GenePharma Company (Shanghai, China).
The sequences of siRNAs were disclosed as: KPNA2-
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and antisense, 5’-TTUGCUUAACCGUACCACCACUU-
3’; KPNA2-Si467: sense, 5’-CCGGGUGUUGAUUCCGAA
TT-3’, and antisense, 5’-TTGGCCCACAACUAAGGCU
U-3’; PLAG1-Si: sense, 5’-GCACAUGGCUACUCAUUC
UTT-3’, and antisense, 5’-TTCGUGUACCGAUGAGUAA
GA-3’.
KPNA2 expression vectors and siRNAs were transfected
into HCC cells by Lipo2000 reagent (Life Technologies,
USA) according to the manufacturer’s instructions. The
expression of KPNA2 or PLAG1 in the transfected cells
was examined by RT-PCR and Western Blot after 48 h.Figure 1 Assistance of PLAG1 nucleus shuttling by KPNA2. (a) The ass
proceeding to IP was designated as input and samples pulled down by IgG a
examined to exclude unspecific bind by KPNA2 antibody. (b) The expression
Huh7 cells (GFP) or Huh7 cells transfected with KPNA2 expression plasmids (C
(right panel) total protein in control SMMC7721 cells (Scramble) or SMMC772
accumulation of KPNA2 could be manipulated by KPNA2 expression plasmids
expression (down panel) of PLAG1 in SMMC7721 and Huh7 cells. ACTB and L
nuclearnucleus protein determination respectively. (f) In situ observation of th
immunocytochemistry. Nucleus was stained by DAPI. Cells with KPNA2 overe
transcriptional targets of PLAG1 in SMMC7721 and Huh7 cells. Data representCells transfected with empty vector or a scrambled siRNA
were used as negative controls. We acquired cell clones
with KPNA2 over-expression using puromycin.
Cell proliferation assay
Approximately 2 × 103 HCC cells were plated in 96-well
plates. Cell proliferation was assessed using the Cell
Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan)
according to the manufacturer’s protocol. All of the exper-
iments were performed in triplicate. The cell proliferation
curves were plotted using the absorbance at each time
point.ociation of KPNA2 and PLAG1 was assayed by Co-IP, protein samples not
ntibody was used as negative control. Unassociated protein ACTB was
of KPNA2 (left panel) and PLAG1 (right panel) total protein in control
lone1 and Clone2). (c) The expression of KPNA2 (left panel) and PLAG1
1 cells transfected with KPNA2 siRNAs (Si144 and Si467). (d) Nucleus
and siRNAs. (e) The nucleus accumulation (up panel) and cytoplasm
amin B antibody were applied for endogenous antibody for total and
e nucleus accumulation of PLAG1 in Huh7 cell line was investigated by
xpression was marked by the white arrows. (g-h) Expression of
s as mean ± s.d. ★ represents statistical significance.
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The 24-well Boyden chamber with 8-μm pore size poly-
carbonate membrane (Corning, NY) was used to analyze
the migration of tumor cells. Approximately 1 × 104
HCC cells were plated into chamber. HCC cells were
plated into chamber 36 h after siRNA transfection (for
both KPNA2 and PLAG1). About 24 hours later, the
non-migrating cells on the upper chambers were re-
moved using a cotton swab and migratory cells were
stained. Cell number were plotted as the average num-
ber of migrated cells from 5 random microscopic fields.
Co-immunoprecipitation (Co-IP)
Cell lysates were prepared from SMMC7721 and Huh7
cells without any KPNA2 manipulation. KPNA2 poly-
clonal antibody described above was diluted 1:1000.
Co-immunoprecipitation was performed according toFigure 2 PLAG1 is essential for the role of KPNA2 in proliferation and
assayed every 12 hours for two days in three independent experiments. ★
(c-d) The number of migratory HCC cells was calculated with crystal violet
panel show mean the average count of six random microscopic fields andmanufacture of Pierce Classic IP Kit (USA). Briefly,
the protein extracts were incubated with either a spe-
cific primary antibody or a IgG control antibody over-
night at 4°C. Five percent of whole cell lysates was
saved as input controls. Immune complexes were col-
lected on Protein A agarose. After washing three times
with 0.7 ml of protein lysis buffer, the precipitates
were boiled and analyzed using SDS/PAGE (10–12% gel)
followed by western blotting to analyze the protein.
Immunocytochemistry
Huh7 Cells with KPNA2 over-expression and negative
controls (1:2) were plated into chamber. After 36 h, cells
were fixed with 1% paraformaldehyde for 5 min at room
temperature. For immunostaining, PLAG1 antibody
(Aogma, USA), KPNA2 antibody (BD Biosciences), DAPI
(Invitrogen, USA) and cross-adsorbed secondary antibodiesinvasion of tumor cells. (a-b) The cell proliferation of HCC cells was
represents statistical significance compared to Scramble or GFP cells.
staining and representative fields were exhibited. Bar graphs in left
the mean SEM. ★ represents statistical significance.
Table 1 The clinico-pathological characteristics of patients
according to nuclear enrichment of PLAG1
Variate PLAG1▲ P-value
Negative Positive
All cases 171 143
Age (year), ≤60:>60 132:39 113:30 0.785
Gender, male:female 149:22 128:15 0.599
Child-Pugh, A:B 155:16 130:13 0.680
HBs antigen, positive:negative 150:21 123:20 0.737
HBe antigen positive:negative 35:136 31:112 0.889
AFP (ug/L), >20:≤20 62: 109 54: 89 0.815
Tumor size (cm), >5:≤5 81:90 88:55 0.030*
No. tumor, Solitary:Multiple 140:31 111:32 0.451
Edmondson Grade, I + II:III + IV 22:149 12:131 0.274
Vascular invasion, Present:Absent 99:72 88:55 0.564
Micro-metastases, Present:Absent 123:48 107:36 0.610
▲: PLAG1 status in tumoral tissues. *represents statistical significance.
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LSM 510.
Immunohistochemical analysis
The immunohistochemical staining was performed on
the TMA using a two-step immunoperoxidase tech-
nique. The KPNA2 polyclonal antibody (BD, USA) di-
luted 1:1000 and PLAG1 polyclonal antibody (Biossy,
USA) diluted 1:200 were used as primary antibody.
Briefly, after heating the sections in 10 mmol/L citrate
buffer for antigen retrieval, sections were incubated first
with primary antibodies, and then with secondary anti-
body for an hour at room temperature. The staining was
assessed by two separate investigators who were blind to
the patient characteristics. The positive KPNA2 and
PLAG1 staining was defined as nucleus staining in more
than 5% cells [12].
Statistical analysis
We defined the recurrence-free survival (RFS) and over-
all survival (OS) as the interval of tumor resection to the
detection of tumor recurrence and the subject’s death of
HCC. All statistical analyses were carried out using SPSS
version 16.0 software. A one-way analysis of variance,
the chi-square test and the two-tailed Student’s t-test
were performed when appropriate. Survival curves were
calculated using the Kaplan-Meier method and com-
pared using a log-rank test. P-value less than 0.05 were
considered to be statistically significant.
Results
Transcriptional factor PLAG1 is promoted into nucleus
by KPNA2
We applied co-immunoprecipitation using a polyclonal
antibody of KPNA2 and proteins acquired from the as-
says were used for detection of PLAG1, with ACTB as a
negative control. The association of PLAG1 with KPNA2
was confirmed in two HCC cell lines, as PLAG1, but not
ACTB, could be detected in the precipitate enriched by
KPNA2 antibody (Figure 1a). Next, In vitro models were
applied to explore whether the association would be
functional for PLAG1 in nucleus shuttling. Firstly, the
overexpression of KPNA2 in Huh7 was validated in two
different clones by stable transfection with KPNA2 ex-
pression vector (Figure 1b, designated as Clone1, Clone2).
Then, we established a small-interfering RNA (siRNA)-
mediated loss of KPNA2 expression in SMMC7721 cells
(Figure 1c, designated as si144 and si467). KPNA2 acts as
regulator of nucleus import, the translocation of KPNA2
into nucleus partly represented the biological effect of
KPNA2 and was determined in HCC cell lines of in vitro
models. Cell fractionation followed by immunoblotting in-
dicated that intervention of KPNA2 could modulate the
nucleus KPNA2 expression (Figure 1d), suggesting ourin vitro models could be applied to investigate the role of
KPNA2 in nucleus shuttling.
Nucleus and cytoplasm protein was extracted from
HCC cell lines with KPNA2 manipulation and were ap-
plied for detection of PLAG1 protein. The results
indicated that nucleus expression of PLAG1 could be
significantly increased in Huh7 cells with KPNA2 over-
expression. Besides, inhibition of KPNA2 could remark-
ably decrease the expression level of PLAG1 in nucleus
(Figure 1e). Conversely, PLAG1 protein in cytoplasm
was slightly decreased after ectopic over-expression of
KPNA2 and was mildly increased by inhibition of KPNA2
(Figure 1e), which were consistent with the result that
PLAG1 expression remained unchanged after manipula-
tion of KPNA2 (Figure 1b-c). Immunocytochemistry was
applied to observe the increased nucleus shuttling of
PLAG1 in Huh7 cells with over-expressed KPNA2 com-
pared with control Huh7 cells (Figure 1f). We then sought
to validate the association between KPNA2 and PLAG1
by investigating the transcriptional regulation of down-
stream molecular by PLAG1. Several definite targets
of PLAG1 were analyzed by qRT-PCR. Remarkably, we
observed that the expression of IGF-II, CRABP2 and
CRLF1 were significantly inhibited by KPNA2 siRNAs
in SMMC7721 cells (Figure 1g). Increment of IGF-II,
CRABP2 and CRLF1 were induced by KPNA2 over-
expression in Huh7 cells (Figure 1h). Furthermore, we
transfected PLAG1 siRNA into Huh7 cells of KPNA2
over-expressed clones and found that transcriptional
up-regulation of IGF-II, CRABP2 and CRLF1 were sig-
nificantly counteracted by PLAG1 inhibition (Figure 1h).
In sum, we revealed that KPNA2 might act as a vehicle
to transport PLAG1 into nucleus to regulate down-
stream effectors.
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migration of HCC
We then aimed to explore whether the interaction be-
tween KPNA2 and PLAG1 had functional significance in
HCC. Firstly, we measured the proliferative capability of
tumor cells by CCK-8 assays. The proliferation of HCC
cells was significantly retarded by KPNA2 inhibition
(Figure 2a) and accelerated by KPNA2 overexpression
(Figure 2b). It is noteworthy that PLAG1 inhibition
could significantly counterweighed the effect of KPNA2
overexpression in Huh7 cells (Figure 2b). Evidences have
revealed the involvement of IGF-II in metastasis of HCC
cells [19,20]; we then sought to determine whether
KPNA2 could promote the metastasis of HCC cells
through PLAG1. Transwell assay was applied to findFigure 3 The representative staining of KPNA2 and PLAG1 in clinical
shown to define four groups: KnPn, low KPNA2 and low PLAG1 enrichment
KpPn, high KPNA2 and low PLAG1 enrichment in nucleus; KpPp, high KPNA2
tissue (NT) was shown as control to tumoral tissues. Magnification scales rethat inhibition of KPNA2 lead to decrease of migratory
cells by nearly 40-50% in SMMC7721 cell lines (Figure 2c).
KPNA2 over-expression could remarkably increase the
migratory ability of Huh7 HCC cells in vitro and PLAG1
knock-down could significantly offset the effect of KPNA2
over-expression in HCC cell metastasis (Figure 2d). Col-
lectively, the results indicated that the role of KPNA2 in
proliferation and migration relied on PLAG1.
The co-enrichment of nucleus PLAG1 and KPNA2 in vivo
To determine the in vivo interaction and clinical signifi-
cance of KPNA2 and PLAG1, we performed an immu-
nohistochemical analysis of KPNA2 and PLAG1 in a
tissue microarray including 314 HCC patients with
tumoral (T) and corresponding non-tumoral (NT) insamples included in TMA. IHC staining of four tumoral tissues (T) was
in nucleus; KnPp, low KPNA2 and high PLAG1 enrichment in nucleus;
and high PLAG1 enrichment in nucleus. One paired non-tumoral
present 100 μm.
Table 2 The co-enrichment of KPNA2 and PLAG1 in both tumoral (T) and non-tumoral (NT) tissues
Staining
PLAG1 KPNA2 Correlation (PLAG1/KPNA2)






Negative 171 237 162 303 P-value <0.001 P-value <0.001
▲Represent the comparison of PLAG1 or KPNA2 nuclear staining between T and NT tissues.
※Represent the correlation of PLAG1 and KPNA2 nuclear staining in T or NT tissues.
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in cells of tumoral (T) and non-tumoral (NT) tissues, we
defined the contents of KPNA2 and PLAG1 as positive
or negative (Figure 3) and subdivided all patients into these
groups: KnPn (NN = 117, NNT = 235), negative KPNA2 and
negative PLAG1 enrichment in nucleus; KnPp (NN = 45,
NNT = 68), negative KPNA2 and high PLAG1 enrichment
in nucleus; KpPn (NN = 54, NNT = 2) positive KPNA2 and
negative PLAG1 enrichment in nucleus; KpPp (NN = 98,
NNT = 9), positive KPNA2 and positive PLAG1 enrich-
ment in nucleus (Figure 3). Consistent with previous re-
port [12], the positive KPNA2 expression was almost
tumor specific, as only non-tumoral tissues of 11 HCC pa-
tients showed positive KPNA2 expression. Besides, the
positive nucleus staining of PLAG1 in tumors was more
frequent than in non-tumoral tissues (Table 2), further
supporting the role of PLAG1 in HCC. Furthermore, we
found that patients with positive KPNA2 expression wereFigure 4 The prognostic significance of KPNA2 and PLAG1 expression
survival (b) in HCC patients stratified by KPNA2 expression status. Kaplan-M
HCC patients stratified by PLAG1 expression status. The survival curves werinclined to harbor positive PLAG1 expression in both T
and NT tissues (Table 2). The results revealed the inter-
action between KPNA2 and PLAG1 in vivo.
The tumoral PLAG1 expression correlates with survival of
HCC patients
Previous report has indicated the clinical significance of
positive KPNA2 in tumoral tissue as prognostic predictor.
Consistently, we determined that HCC patients with posi-
tive KPNA2 expression in tumoral tissue would develop
more frequent recurrence and death (Figure 4a-b). Given
that PLAG1 is an indispensable mediator for the function
of KPNA2 in HCC cells, we hypothesized that nucleus
enrichment of PLAG1 in tumoral tissue might be a
malignant character of HCC. Through analysis of the
association between the PLAG1 expression and clinic-
pathological characteristics, we determined that the
positive PLAG1 expression was associated with larger. Kaplan-Meier analyses of recurrence-free survival (a) and overall
eier analyses of recurrence-free survival (c) and overall survival (d) in
e compared using a Long-rank test.
Table 3 The clinico-pathological characteristics of patients




All cases 53 99
Age (year), ≤60:>60 38:15 82:17 0.143
Gender, male:female 48:5 87:12 0.789
Child-Pugh, A:B 46:6 85:10 1.000
HBs antigen, positive:negative 47:6 86:13 0.803
HBe antigen positive:negative 7:46 22:77 0.201
AFP (ug/L), >20:≤20 20: 33 36: 63 0.862
Tumor size (cm), >5:≤5 30:23 67:32 0.005*
No. tumor, Solitary:Multiple 44:9 81:19 0.607
Edmondson Grade, I + II:III + IV 3:50 8:91 0.748
Vascular invasion, Present:Absent 35:18 67:32 0.858
Micro-metastases, Present:Absent 41:12 72:27 0.566
▲: PLAG1 status in tumoral tissues. *represents statistical significance.
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whether positive PLAG1 expression level correlated
with outcome of HCC patients after hepatectomy. We
found that patients with positive PLAG1 expression would
have poorer prognosis including recurrence free survival
(RFS, Figure 4c) and overall survival (OS, Figure 4d) of
HCC patients after hepatectomy. Multivariate analysis re-
vealed that PLAG1 could be an independent factor for
RFS and OS of HCC patients after hepatectomy (Table 3).
In sum, the result indicated that PLAG1 was a novel prog-
nostic predictor for HCC patients.
The positive PLAG1 expression is the only predictor for
survival of KPNA2-positive HCC
Furthermore, we found that patients with positive
KPNA2 and positive PLAG1expression (KpPp) in tumor
have the poorest RFS and OS compared to other groupsFigure 5 The prognostic significance of the interaction between KPNA
(a) and overall survival (b) of HCC patients divided into four subgroups de
Long-rank test. ★ represents statistical significance; NS represents no signif(Figure 5a-b), suggesting the combination of high KPNA2
and PLAG1 density in nucleus would add accuracy to pre-
dict the prognosis of HCC patients. It is noteworthy that
the differential prognosis between PLAG1-negative HCC
patients with positive or negative KPNA2 staining shows
no significance (Figure 5a, RFS: KpPn vs KnPn, p = 0.226;
Figure 5b, OS: KpPn vs KnPn, p = 0.438), confirming the
clinical importance of PLAG1 for the role of KPNA2 in
HCC. However, for patients with positive KPNA2 expres-
sion, the status of PLAG1 in nucleus could significantly
associate with tumor size (Table 3) and predict the RFS
and OS (Figure 5a, RFS: KpPn vs KpPp, p = 0.001; Figure 5b,
OS: KpPn vs KpPp, p = 0.001). Furthermore, multivariate
analysis was applied to determine that the positive PLAG1
expression was the risk factor for prognosis of HCC pa-
tients (Table 4) and the only risk factor for prognosis of
HCC patients with positive KPNA2 expression (Table 5).
Collectively, the results revealed that PLAG1 was essential
for clinical significance of KPNA2 and would add accuracy
to stratify HCC patients with poor prognosis.
Discussion
The nucleus transport system circulates various signal-
ing molecules between the cytoplasm and nucleus.
Karyopherins are one group of carrier proteins involved
in the selective nucleocytoplasmic transport. Accumulat-
ing evidences have identified the critical roles of karyo-
pherins in malignant diseases and KPNA2 gains the
most attention [21-23]. Previous report has measured
the gene expression profiling of karyopherins in HCC
and found overexpressed KPNA2 could promote the
proliferation of HCC cells [7]. Here, our results demon-
strated that KPNA2 could significantly enhance the mi-
gratory ability of HCC cells. However, in vivo evidences
should be acquired to support our results in the future.
One of the prominent of the cargo proteins of KPNA2
is the transcriptional factor PLAG1, previous evidence
has illustrated that pleomorphic adenoma gene 1 (PLAG1)2 and PLAG1. Kaplan-Meier analyses of recurrence free survival
scribed in Figure 3. The survival curves were compared using a
icance.
Table 4 Multivariate analyses of the recurrence-free survival (RFS) and overall survival (OS) in 314 HCC patients stratified
by PLAG1 status
Variate▲ RFS OS
HR (95% CI) P value HR (95% CI) P value
Tumor size, >5 cm 1.061 (1.019-1.105) 0.004 1.081 (1.037-1.128) 0.000
Vascular invasion 1.379 (1.005-1.893) 0.046 1.386 (0.965-1.989) 0.077
HBe antigen positive – - 1.543 (1.068-2.229) 0.021
No. tumor: multiple 1.444 (1.108-1.880) 0.006 1.484 (1.141-1.930) 0.003
PLAG1 Positive 1.766 (1.315-2.371) 0.000 1.589 (1.138-2.220) 0.007
Edmondson Grade, III + IV 1.139 (0.652-1.987) 0.648 0.953 (0.507-1.791) 0.882
▲Variates significant in Univariate analyses were applied here.
HR, Hazard ratio; CI, Confidence interval.
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and proved that a predicted nuclear localization sequence
(NLS) composed of short stretches of basic amino acids
was essential for physical interaction of PLAG1 with
KPNA2 [13]. Also, researchers have illustrated that the
activation of PLAG1 is considered to play important roles
in the pathogenesis of various types of cancers [24,25]. Re-
cent report indicates that PLAG1 might be involved in
regulatory gene work of hepatoblastoma, malignant liver
tumor commonly occurred in childhood [26], suggesting a
potential role of PLAG1 in malignant liver diseases. How-
ever, the involvement of PLAG1 in the role of KPNA2 in
HCC remains elusive. Collectively, we aimed to explore
the association between KPNA2 and PLAG1. We found
that the nucleus import of PLAG1 was aided by KPNA2
and would amplify the transcriptional activities of PLAG1
in HCC. Several genes including IGF-II, CRABP2, CRLF1,
CRIP2, which are transcriptional targets of PLAG1, could
be up-regulated by enhanced KPNA2. IGF-II is frequently
up-regulated in HCC and was enriched in the prolifera-
tion subclass of the molecular classification of HCC [27].
Besides, inhibition of IGF-II could impair the proliferation
and invasive activities of HCC cells [20]. Furthermore, in-
hibition of PLAG1 in cell clones with stable KPNA2 over-
expression could abolish the up-regulation of these genes
and could counteract the pro-tumoral effects of KPNA2.
The result implied that downstream molecular of PLAG1Table 5 Multivariate analyses of the recurrence-free survival (R
KPNA2 expression (KPPn VS KpPp, N = 152)
Variate▲ RFS
HR (95% CI)
Tumor size, >5 cm –
Vascular invasion 1.361 (0.898-2.064)
HBe antigen positive 1.267 (0.799-2.010)
No. tumor: multiple 1.227 (0.845-1.784)
PLAG1 Positive 1.749 (1.146-2.670)
▲Variates significant in Univariate analyses were applied here.
HR, Hazard ratio; CI, Confidence interval.such as IGF-II might be partly responsible for the role
of KPNA2 in HCC. Although we revealed PLAG1 would
be a critical mediator for KPNA2, it is noteworthy that
whether other transcriptional factors carried into nucleus
by KPNA2 might participate in HCC regulation need to
be explored.
Cancer classification using biomarkers may effectively
define the risk of recurrence, which allows for the use of
appropriate treatments to acquire a better prognosis.
The prognosis of patients with positive KPNA2 expres-
sion could be clustered by the status of PLAG1 nucleus
enrichment, validating that the biological effects of
KPNA2 relied on the interaction with PLAG1. Besides,
for the subgroup of patients with negative PLAG1 ex-
pression, the prognostic value of KPNA2 came to be
lost, further confirming that inhibition of PLAG1 could
significantly retard the role of KPNA2 in tumor growth
and metastasis in vitro as shown in Figure 2b and 2d.
Combined with nucleus enrichment of PLAG1, the posi-
tive KPNA2 status would be more accurate to predict
the prognosis of HCC patients after hepatectomy. Pa-
tients with co-existence of positive KPNA2 expression
and positive PLAG1 expression should be closely moni-
tored and receive appropriate adjuvant therapies. How-
ever, further investigation should be done to validate the
prognostic value of KPNA2 and PLAG1 in other cohort
of HCC patients, which would be promising for clinicalFS) and overall survival (OS) in HCC patients with positive
OS
P value HR (95% CI) P value
– 1.062 (0.757-1.121) 0.157
0.146 1.274 (0.785-2.067) 0.327
0.315 1.387 (0.834-2.308) 0.208
0.282 1.183 (0.801-1.747) 0.399
0.010 1.662 (1.007-2.744) 0.047
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http://www.jeccr.com/content/33/1/61application to reduce the false positive rate to identify
and monitor patients with high recurrent risk after
hepatectomy.
Conclusions
PLAG1 could be impelled into nucleus by interaction
with KPNA2, adapter acting in nucleus protein import.
Co-enrichment of KPNA2 and PLAG1 in nucleus is ob-
served in clinical samples. The increment of proliferative
and metastatic abilities by KPNA2 can be significantly
retarded by PLAG1 inhibition. Positive expression of
both PLAG1 and KPNA2 could predict prognosis of
HCC patients after hepatectomy Furthermore, the posi-
tive PLAG1 expression is the only risk factor for recur-
rence free survival and overall survival by multivariate
analyses of patients with positive KPNA2 expression,
further indicating the clinical significance of PLAG1
interaction with KPNA2 and harbor great applicability
to distinguish HCC patient to be closely monitored after
hepatectomy.
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